GlobalData on MSN5d
Royalty Pharma pays $250m for rights to Biogen’s lupus drugRoyalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, ...
StockStory.org on MSN8d
Royalty Pharma Earnings: What To Look For From RPRXHealthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings tomorrow morning. Here’s what to look ...
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...
Q4 2024 Earnings Call Transcript February 11, 2025 Royalty Pharma plc misses on earnings expectations. Reported EPS is ...
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback